The new 2025 catalogue is coming soon… with some big changes
You spoke and we listened! We are updating our catalogue and some of our EQA schemes based on your feedback to better meet the needs of laboratories. We have reduced the maximum number of molecular pathology cases from ten to five, to save analysis costs and time. We are increasing the number of schemes for […]
EMQN to introduce innovative EQA Scheme for MT-RNR1 POCT
As the healthcare landscape has begun to rely increasingly on the use of point-of-care testing at, or close to, the patient’s bedside, it is crucial to ensure those tests are accurate and reliable, since immediate clinical decisions are based on the outcomes where even the slightest error could have profound consequences. EMQN CIC has introduced […]
EMQN & SensID launch ctDNA extraction EQA scheme
EMQN CIC and SensID GmbH are pleased to announce a strategic partnership to deliver a new External Quality Assessment (EQA) / Proficiency Testing (PT) scheme for circulating tumour DNA (ctDNA) extraction from plasma. Background The use of molecular testing to aid in determining therapy options for the treatment of non-small cell lung cancer (NSCLC) is now […]
Introducing the new look EMQN strategy and brand
To consolidate our position as the leading global provider of quality assurance services and knowledge to the human molecular pathology and genetics testing community, we have refined our strategy and launched a distinctive new brand and website. Our aim with this is to better reach new laboratories that could benefit from our help, to help […]
EMQN join DEVOTE programme
EMQN CIC are delighted to be part of the DEVOTE programme, working with the partners (genedrive, Chromition, APIS Assay Technologies Ltd., Manchester University NHS Foundation Trust, Health Innovation Manchester) to deliver EQA for point-of-care testing in pharmacogenetics. Ensuring the delivery of high quality testing to support personalised treatment at the right time to improve patient […]
EAA/EMQN best practice guidelines for molecular diagnosis of Y-chromosomal microdeletions: State of the art 2023
[Correction added on 25 October 2023, after first online publication: Figure A1 has been replaced in this version.] Abstract Testing for AZoospermia Factor (AZF) deletions of the Y chromosome is a key component of the diagnostic workup of azoospermic and severely oligozoospermic men. This revision of the 2013 European Academy of Andrology (EAA) and EMQN […]